(Reuters) - Advanced Medical Optics Chief Executive James Mazzo, responding to a critical letter from ValueAct, said he was "surprised and disappointed" by ValueAct's opposition to the $4.23 billion hostile bid for Bausch & Lomb.
Mazzo said this was "especially hard to understand given expressed interest on June 12th in investing $700 million in equity in a Bausch & Lomb acquisition and your reaffirmation of a desire to participate in financing the transaction as recently as July 5."
Read more at Reuters.com Government Filings News
Mazzo said this was "especially hard to understand given expressed interest on June 12th in investing $700 million in equity in a Bausch & Lomb acquisition and your reaffirmation of a desire to participate in financing the transaction as recently as July 5."
Read more at Reuters.com Government Filings News
No comments:
Post a Comment